Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin added to Hydroxychloroquine in ICU Patients with COVID-19
2020-001456-18Phase 3Terminated
- Sponsor
- Donatio intensivistam
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in coronavirus disease 2019 (COVID-19) comparing Hydroxychloroquine + azithromycin with Control (standard of care) (2 arms). Primary endpoint: Primary composite endpoint. Started Apr 2020; status: terminated.
02
Drugs
azithromycinhydroxychloroquine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001456-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001456-18.